These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9556934)

  • 1. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests.
    Labuhn K; Valanis B; Schoeny R; Loveday K; Vollmer WM
    Cancer Nurs; 1998 Apr; 21(2):79-89. PubMed ID: 9556934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute symptoms associated with antineoplastic drug handling among nurses.
    Valanis BG; Vollmer WM; Labuhn KT; Glass AG
    Cancer Nurs; 1993 Aug; 16(4):288-95. PubMed ID: 8402605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures.
    Everson RB; Ratcliffe JM; Flack PM; Hoffman DM; Watanabe AS
    Cancer Res; 1985 Dec; 45(12 Pt 1):6487-97. PubMed ID: 4063994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenicity in urine from nurses handling cytostatic agents.
    Benhamou S; Callais F; Sancho-Garnier H; Min S; Courtois YA; Festy B
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1489-93. PubMed ID: 3595674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials.
    DeMéo MP; Mérono S; DeBaille AD; Botta A; Laget M; Guiraud H; Duménil G
    Int Arch Occup Environ Health; 1995; 66(6):363-8. PubMed ID: 7782118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents.
    Santos AN; Oliveira RJ; Pessatto LR; Gomes RDS; Freitas CAF
    Int J Pharm Pract; 2020 Oct; 28(5):506-511. PubMed ID: 31663186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking.
    Bos RP; Leenaars AO; Theuws JL; Henderson PT
    Int Arch Occup Environ Health; 1982; 50(4):359-69. PubMed ID: 6757139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nurses' internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study.
    Villa A; Molimard M; Sakr D; Lassalle R; Bignon E; Martinez B; Rouyer M; Mathoulin-Pelissier S; Baldi I; Verdun-Esquer C; Canal-Raffin M
    Int Arch Occup Environ Health; 2021 Nov; 94(8):1839-1850. PubMed ID: 34021808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel.
    Valanis BG; Vollmer WM; Labuhn KT; Glass AG
    Am J Hosp Pharm; 1993 Mar; 50(3):455-62. PubMed ID: 8442461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse health effects among nurses and clinical pharmacists handling antineoplastic drugs: Adherence to exposure control methods.
    Elshaer N
    J Egypt Public Health Assoc; 2017 Sep; 92(3):144-155. PubMed ID: 30341993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary biological monitoring markers of anticancer drug exposure in oncology nurses.
    Newman MA; Valanis BG; Schoeny RS; Hee SQ
    Am J Public Health; 1994 May; 84(5):852-5. PubMed ID: 8179062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Workers' Knowledge, Perceptions, and Behaviors Regarding Antineoplastic Drugs: Survey From British Columbia, Canada.
    Hon CY; Teschke K; Shen H
    J Occup Environ Hyg; 2015; 12(10):669-77. PubMed ID: 25897641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacists.
    El-Ebiary AA; Abuelfadl AA; Sarhan NI
    J Appl Toxicol; 2013 Mar; 33(3):196-201. PubMed ID: 21935972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of the salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drugs.
    Friederich U; Molko F; Hofmann V; Scossa D; Hann D; Würgler FE; Senn HJ
    Eur J Cancer Clin Oncol; 1986 May; 22(5):567-75. PubMed ID: 3533554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring mutagenicity in urine and peripheral blood lymphocytes of pharmacists occupationally exposed to anticancer drugs.
    Elliott G; Ferguson L; Everts R; Edwards R
    N Z Med J; 1990 Jan; 103(882):13-6. PubMed ID: 2406649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methods for the biomonitoring of nurses handling antitumor drugs.
    Thiringer G; Granung G; Holmén A; Högstedt B; Järvholm B; Jönsson D; Persson L; Wahlström J; Westin J
    Scand J Work Environ Health; 1991 Apr; 17(2):133-8. PubMed ID: 2047815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan.
    Yoshida J; Kosaka H; Tomioka K; Kumagai S
    J Occup Health; 2006 Nov; 48(6):517-22. PubMed ID: 17179646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs.
    Tuffnell PG; Gannon MT; Dong A; DeBoer G; Erlichman C
    Am J Hosp Pharm; 1986 Feb; 43(2):344-8. PubMed ID: 3513557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists.
    Valanis B; Vollmer WM; Steele P
    J Occup Environ Med; 1999 Aug; 41(8):632-8. PubMed ID: 10457505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of handling injectable antineoplastic agents.
    Anderson RW; Puckett WH; Dana WJ; Nguyen TV; Theiss JC; Matney TS
    Am J Hosp Pharm; 1982 Nov; 39(11):1881-7. PubMed ID: 6756133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.